$NOVN #Novartis AG NOVARTIS: Safety review of Beovu concludes about risks | BUY | CHF105 vs. CHF107 (+27%): NOVARTIS - BUY | CHF105 vs. CHF107 (+27%) Safety review of Beovu concludes about risks The warning about Beovu dated February 2020… https://t.co/XQJutPJzUb #equity #stocks https://t.co/JDY0CYdYA7